
|Videos|December 2, 2020
Single administration of intracameral bimatoprost implant: IOP lowering, safety
Author(s)David Hutton, Alex Delaney-Gesing
Michael R. Robinson, MD, shares the highlights of the study "Single administration of intracameral bimatoprost implant 10 µg: IOP lowering and safety," presented during the virtual AAO 2020 meeting.
Advertisement
Michael R. Robinson, MD, vice president, Global Therapeutic Area Head, Ophthalmology at Allergan, shares the highlights of the study "Single administration of intracameral bimatoprost implant 10 µg: IOP lowering and safety," presented during the virtual AAO 2020 meeting.
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
Iolyx Therapeutics and Laboratoires Théa enter into agreement over ILYX-002 for the treatment of OSD
2
PainReform launches development plan for OcuRing-K, readies phase 2 trial
3
Avisi Technologies treats first patient in SAPPHIRE trial for glaucoma
4
FDA approves Amneal Pharmaceuticals' cyclosporine ophthalmic emulsion 0.05%
5















































.png)


